MADISON, Wis.--(BUSINESS WIRE)--Stratatech Corp., a regenerative medicine company focused on the development and commercialization of cell-based, tissue-engineered skin substitute products, today announced that it has successfully completed the multi-center, 15-patient clinical trial of its StrataGraft® living human skin substitute. The company achieved its primary clinical endpoint for the trial, autograft engraftment comparable to the standard of care. No adverse or serious adverse events were deemed to be associated with exposure to StrataGraft® skin substitute. The clinical trial data was presented Saturday at the annual meeting of the American Association for the Surgery of Trauma by the University of Wisconsin’s Michael J. Schurr, M.D., the trial’s principal clinical investigator.
